Lymphoma cell-of–origin assignment by gene expression profiling is clinically meaningful across broad laboratory contexts

Cell-of-origin (COO) assignment for diffuse large B-cell lymphoma (DLBCL) using formalin-fixed paraffin embedded (FFPE) lymph nodes by Lymph2Cx assay on the NanoStringnCounter was comparable to microarray-based methods using fresh tissue in demonstrating prognostic significance (Scott et al, 2014). The assay provided an accessible means of translating gene expression profiling into standard practice with both prognostic and therapeutic implications (Pasqualucci et al, 2011; Dunleavy et al, 2014). We sought to determine if clinically meaningful results were obtainable from small core biopsies and EDTA (ethylenediaminetetraacetic acid) decalcified trephine biopsies.